SCHEMBL2930841

SCHEMBL2930841

CCOC(=O)c1c(SC)ccc([N+](=O)[O-])c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1C Q13936 2/20 0.48
GSTP1 P09211 2/20 0.46
GSTM2 P28161 2/20 0.46
PRKCZ Q05513 1/20 0.44
MAPT P10636 5/20 0.43
LMNA P02545 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 4/20 0.42
POLB P06746 2/20 0.42
GALR2 O43603 1/20 0.42
MITF O75030 1/20 0.42
HSP90AA1 P07900 1/20 0.42
HPGD P15428 1/20 0.42
XBP1 P17861 1/20 0.42
CCR6 P51684 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPC1 O15118 2/20 0.42
AR P10275 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925221 0.82 GSTP1 (0.53) GSTP1GSTM2PRKCZMAPTLMNA
SCHEMBL940019 0.81 PRKCZ (0.45) PRKCZMAPTLMNANPSR1KMT2A
SCHEMBL2930533 0.80 CACNA1C (0.45) CACNA1CPRKCZMAPTLMNANPSR1
SCHEMBL15808259 0.80 ALDH1A1 (0.52) PRKCZMAPTLMNANPSR1TDP1
SCHEMBL27362998 0.79 ALDH1A1 (0.48) PRKCZMAPTLMNANPSR1KMT2A
SCHEMBL2932351 0.75 POLB (0.51) PRKCZMAPTTDP1KMT2AALDH1A1
SCHEMBL3369777 0.74 ALDH1A1 (0.41) PRKCZMAPTLMNANPSR1KMT2A
SCHEMBL2931469 0.72 ALDH1A1 (0.52) MAPTLMNATDP1KMT2AALDH1A1
SCHEMBL10567759 0.72 ALDH1A1 (0.50) CACNA1CPRKCZMAPTLMNATDP1
SCHEMBL4728649 0.72 ALDH1A1 (0.54) CACNA1CMAPTLMNANPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910314-B1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2010-09-15 EP disclosed
US-20080306064-A1 Benzimidazole Derivatives BROWN LYNDON NIGEL 2008-12-11 US disclosed
EP-1910314-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES Novartis AG (CH) 2008-04-16 EP disclosed
WO-2007009774-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306064-A1 Benzimidazole Derivatives PPARG, PPARD, BRD4 CACNA1C 3982/4885GSTP1 1454/4885GSTM2 2657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.